Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
18
Sex
Women only
Ages
Ages 18 Years to 100 Years
Primary completion
2025-05-30
Last update
2025-06-29

What this trial studies

The study aimed to establish the effectiveness of an immersive mindfulness virtual reality intervention using fractal software for women experiencing menopausal symptoms. It was hypothesised that post immersive virtual reality fractal mindfulness intervention would result in higher levels of sexual function, wellbeing and cognitive mindfulness with lower levels of menopause symptoms. It was further hypothesised that in physiological responses, the pulse rate would be lower post intervention per session and an overall reduction in pulse rate post intervention. An electroencephalogram will be used to monitor alpha and beta ratios.

Conditions in scope

  • Menopause

Interventions

  • Fractal mindfulness recombination (Device) — Immersive virtual reality using fractal mindfulness software

Who can join

Women only · Ages 18 Years to 100 Years · Accepts healthy volunteers.

Inclusion criteria

  • Must have perceived peri or menopausal symptoms
  • Must have normal or corrected to normal hearing and vision
  • Must be 18 years or older
  • Must have used virtual reality before with no side effects
  • Must have a pulse rate of 60 to 80 beats per minute
  • Must NOT experience seizures
  • Must NOT have coordination difficulties

Exclusion criteria

  • Do not have peri or menopausal symptoms
  • Have coordination difficulties
  • Report having claustrophobia
  • Pulse rate higher than 80 at rest
  • Have sensitivities to flashing lights
  • Are prone to migraine
  • Have seizures Are younger than 18 years old

Eligibility wording paraphrased from the public record. View the full criteria on ClinicalTrials.gov before contacting a site.

Where it’s happening

CityState / RegionFacilitySite status
London School of Social Science and Professions Unknown

Status & timeline

  • Overall status: Completed
  • Study type: Interventional
  • Phase: N/A
  • Start date: 2025-02-02
  • Primary completion: 2025-05-30
  • Last update posted: 2025-06-29
  • First posted: 2025-06-29

Lead sponsor: London Metropolitan University (Other)

For trial site contact information, use the official record at ClinicalTrials.gov. Contact details change frequently and the public record is the source of truth.

Outcome measures

Primary outcomes

  • Menopause symptoms (0, 4 and 8 weeks)
    This 17 item questionnaire consists of a 4 option (0 not at all, 4 a lot) Likert scale that evaluates menopause symptoms. Example symptoms include difficulty concentrating, loss of interest in sex, pain during sex, and vaginal dryness. Areas are divided into vasomotor symptoms, emotional symptoms, local and sexual symptoms, as well as various physiological symptoms. The Cronbach's alpha is…

If you’re reading this trial because you have menopause symptoms now, you don’t have to wait for a trial to access evidence-based care. ClearedRx prescribes the same FDA-approved and compounded HRT products that have been studied in trials like this one for decades.

Important. Information from ClinicalTrials.gov as of May 8, 2026. Trial details (status, sites, contacts, eligibility, outcomes) change frequently — always check the official record at https://clinicaltrials.gov/study/NCT07044284 before contacting a site.

ClearedRx is not affiliated with this trial or its sponsor. We index public-domain ClinicalTrials.gov records to help patients find evidence-based context for menopause care decisions. ClearedRx itself is a telehealth menopause/HRT brand — we do not enroll patients in trials.